Navigation Links
Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--Inflazyme Pharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007, the preliminary results of the Phase 2b CAPSICS study with IPL512,602 showed no statistical or clinical difference between patients who received drug or placebo. However, the placebo response was surprisingly large and consistent across a number of the end-points, which prompted an examination by Inflazyme and its external experts to determine if anything untoward had occurred during the study.

To put the placebo response in perspective, we compared the results of our study to publications of other asthma clinical studies where Asthma Quality of Life was used as an endpoint. Our placebo response was two to three times greater than generally observed. Dr. William Busse and Dr. Mark FitzGerald, two leading clinical asthma experts who reviewed the data, agreed that "the large magnitude of the placebo response is surprising and could potentially obscure any apparent benefits of IPL512,602".

Our medical advisors have offered three possible factors contributing to the high placebo response. First, as is not uncommon, the study did not include placebo treatment during the run-in period at the start of the trial when patients were to be stabilized on their existing therapy. Observing a large placebo effect during this run-in period could have excluded those patients from the study.

Second, subjects were on a background therapy of inhaled corticosteroids and it is not possible to determine if there may have been compliance issues whereby patients were not taking their medications on a consistent basis as prescribed in the run-up to the study. A part of the placebo response might indeed be attributable to patients, once enrolled into the study, paying more attention to their symptoms and becoming more compliant with their background medications.This may have resulted in an improvem
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:4/17/2015)... 2015 Sigma-Aldrich Corporation (NASDAQ: ... High Technology company, today announced the opening of ... and state-of-the-art Cell Culture Technical Center in Singapore.  ... provide customized support to meet customer needs, leveraging ... "Our new Technical Center will significantly enhance our ...
(Date:4/16/2015)... , April 16, 2015 A drug commonly ... eyesight of people with multiple sclerosis (MS), according to a ... Academy of Neurology,s 67th Annual Meeting in Washington, ... "About half of people with MS experience at some ... in which the nerve carrying vision from the eye to ...
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth C. ... & Co., Inc., was elected chairman of the Board of ... Board meeting, PhRMA,s president and CEO John J. Castellani ... 2016.  New Officers Elected to PhRMA Board ... succeeds Ian C. Read , chairman and CEO of ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Epilepsy Drug May Preserve Eyesight for People with MS 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
... BEDMINSTER, N.J. and SYDNEY, April 10, 2012 QRxPharma ... of two Phase 1 studies in healthy volunteers for ... of morphine and oxycodone. The proprietary MoxDuo CR formulation, ... deterrent and tamper resistant features, is designed to provide ...
... April 9, 2012  Legacy ® and Lung ... an actuarial cost-benefit analysis conducted by Milliman Inc., ... that screening 50-64 year olds at high risk ... scans can save more lives, and at lower cost ...
Cached Medicine Technology:QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR 2QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR 3QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR 4Legacy® and Lung Cancer Alliance Hail the Release of New Study Showing Lung Cancer Screening is Cost Effective 2Legacy® and Lung Cancer Alliance Hail the Release of New Study Showing Lung Cancer Screening is Cost Effective 3
(Date:4/18/2015)... "I recognized the need for a better way ... inventor from Cincinnati, Ohio. "This need inspired me to ... Slyde Door to offer an alternative to the conventional ... convenient storage space for an evacuation stretcher. The door ... , This offers added peace of mind to ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Insuranceautoquote.info has ... online auto insurance quotes . , Clients ... a single website. The online environment provides important advantages ... vehicles. , Drivers who do not have coverage ... rates during any season, day or hour. Many agencies ...
(Date:4/18/2015)... NC (PRWEB) April 18, 2015 Patients ... risk of developing mesothelioma later in life, but the ... from mesothelioma that is unrelated to radiation. Surviving Mesothelioma ... on its website. Click here to read it ... Australia compared the cases of 45 patients who had ...
(Date:4/18/2015)... 18, 2015 More than 2000 styles ... at TheCelebrityDresses.com, the #1 online store carrying celebrity inspired ... girls have got their perfect dresses for their prom. ... fashion prom dresses at TheCelebrityDresses.com would be an ideal ... than 2000 prom dresses inspired by the most loved ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as ... the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... , In a turbulent world, people may find themselves in ... be their first move, but some situations can be avoided ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2
... Encephalitis have been found after 36 samples of blood serum ... here were tested, officials said today. // ,Of ... Japanese Encephalitis while the rest were of viral Encephalitis, said ... Medical College here., ,Rathi said since April 1, 171 ...
... prevalence of HIV virus in South Africa may be on ... and Syphilis Antenatal Sero-prevalence Survey for 2005 // that HIV ... had been in 2004 (29.5 per cent) and in 2005 ... today while the latest finding was 'encouraging', there was still ...
... said it has received approval from the Drugs Controller ... for the molecule LL-42 18 (Desoside-P).// ,The ... on the Psoriasis pure compound, LL-42 18, after DCGI ... to be satisfactory., ,Lupin informed the Bombay Stock ...
... In what holds promise for a large number of Alzheimer's ... inch long contraption designed to be implanted under// the skin ... contains a medicine that is slowly pumped into the patient's ... of this implant, the medicine is capable of retarding the ...
... investigating the incidence of breast cancer at Brisbane's ABC headquarters ... ,ABC managing director Mark Scott said that Dr ... panel chaired by Dr Bruce Armstrong. ,Mr Scott ... to work alongside the panel. ,The review panel ...
... police lockups are to be offered immediate access to services ... scheme is already underway in many areas of Scotland like ... ,Funding has been provided to continue this scheme until ... ,Under this scheme the users are assessed ...
Cached Medicine News:Health News:Breast Cancer Review Panel Adds Two Experts 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: